Left Ventricular Hypertrophy and Cerebral Small Vessel Disease: A Systematic Review and Meta-Analysis.
Cerebral hemorrhage
Cerebral small vessel diseases
Hypertrophy, left ventricular
Leukoaraiosis
Meta-analysis
Stroke, lacunar
Journal
Journal of stroke
ISSN: 2287-6391
Titre abrégé: J Stroke
Pays: Korea (South)
ID NLM: 101602023
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
27
11
2019
accepted:
06
03
2020
entrez:
9
7
2020
pubmed:
9
7
2020
medline:
9
7
2020
Statut:
ppublish
Résumé
Left ventricular hypertrophy (LVH) is associated with the risk of stroke and dementia independently of other vascular risk factors, but its association with cerebral small vessel disease (CSVD) remains unknown. Here, we employed a systematic review and meta-analysis to address this gap. Following the MOOSE guidelines (PROSPERO protocol: CRD42018110305), we systematically searched the literature for studies exploring the association between LVH or left ventricular (LV) mass, with neuroimaging markers of CSVD (lacunes, white matter hyperintensities [WMHs], cerebral microbleeds [CMBs]). We evaluated risk of bias and pooled association estimates with random-effects meta-analyses. We identified 31 studies (n=25,562) meeting our eligibility criteria. In meta-analysis, LVH was associated with lacunes and extensive WMHs in studies of the general population (odds ratio [OR]lacunes, 1.49; 95% confidence interval [CI], 1.12 to 2.00) (ORWMH, 1.73; 95% CI, 1.38 to 2.17) and studies in highrisk populations (ORlacunes: 2.39; 95% CI, 1.32 to 4.32) (ORWMH, 2.01; 95% CI, 1.45 to 2.80). The. remained stable in general population studies adjusting for hypertension and other vascular risk factors, as well as in sub-analyses by LVH assessment method (echocardiography/electrocardiogram), study design (cross-sectional/cohort), and study quality. Across LV morphology patterns, we found gradually increasing ORs for concentric remodelling, eccentric hypertrophy, and concentric hypertrophy, as compared to normal LV geometry. LVH was further associated with CMBs in high-risk population studies. s LVH is associated with neuroimaging markers of CSVD independently of hypertension and other vascular risk factors. Our findings suggest LVH as a novel risk factor for CSVD and highlight the link between subclinical heart and brain damage.
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
Left ventricular hypertrophy (LVH) is associated with the risk of stroke and dementia independently of other vascular risk factors, but its association with cerebral small vessel disease (CSVD) remains unknown. Here, we employed a systematic review and meta-analysis to address this gap.
METHODS
METHODS
Following the MOOSE guidelines (PROSPERO protocol: CRD42018110305), we systematically searched the literature for studies exploring the association between LVH or left ventricular (LV) mass, with neuroimaging markers of CSVD (lacunes, white matter hyperintensities [WMHs], cerebral microbleeds [CMBs]). We evaluated risk of bias and pooled association estimates with random-effects meta-analyses.
RESULTS
RESULTS
We identified 31 studies (n=25,562) meeting our eligibility criteria. In meta-analysis, LVH was associated with lacunes and extensive WMHs in studies of the general population (odds ratio [OR]lacunes, 1.49; 95% confidence interval [CI], 1.12 to 2.00) (ORWMH, 1.73; 95% CI, 1.38 to 2.17) and studies in highrisk populations (ORlacunes: 2.39; 95% CI, 1.32 to 4.32) (ORWMH, 2.01; 95% CI, 1.45 to 2.80). The.
RESULTS
RESULTS
remained stable in general population studies adjusting for hypertension and other vascular risk factors, as well as in sub-analyses by LVH assessment method (echocardiography/electrocardiogram), study design (cross-sectional/cohort), and study quality. Across LV morphology patterns, we found gradually increasing ORs for concentric remodelling, eccentric hypertrophy, and concentric hypertrophy, as compared to normal LV geometry. LVH was further associated with CMBs in high-risk population studies.
CONCLUSION
CONCLUSIONS
s LVH is associated with neuroimaging markers of CSVD independently of hypertension and other vascular risk factors. Our findings suggest LVH as a novel risk factor for CSVD and highlight the link between subclinical heart and brain damage.
Identifiants
pubmed: 32635685
pii: jos.2019.03335
doi: 10.5853/jos.2019.03335
pmc: PMC7341009
doi:
Types de publication
Systematic Review
Langues
eng
Pagination
206-224Références
Stroke. 1998 Jul;29(7):1333-40
pubmed: 9660383
Am J Epidemiol. 2003 May 15;157(10):940-3
pubmed: 12746247
Circ Res. 2017 Feb 3;120(3):573-591
pubmed: 28154105
J Am Coll Cardiol. 1999 May;33(6):1685-91
pubmed: 10334443
J Neurol Neurosurg Psychiatry. 2001 Jan;70(1):9-14
pubmed: 11118240
Stroke. 2005 Mar;36(3):546-50
pubmed: 15662040
Am Heart J. 2018 Oct;204:58-67
pubmed: 30077834
Hypertension. 1990 Dec;16(6):692-9
pubmed: 2246035
Stat Med. 2003 Sep 15;22(17):2693-710
pubmed: 12939780
Am J Cardiol. 1986 Feb 15;57(6):450-8
pubmed: 2936235
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
Neurology. 2012 Sep 18;79(12):1215-22
pubmed: 22955138
Stroke. 1996 Aug;27(8):1274-82
pubmed: 8711786
Stroke. 2004 Aug;35(8):1857-61
pubmed: 15218158
Lancet Neurol. 2013 Aug;12(8):822-38
pubmed: 23867200
Stat Med. 2017 Nov 10;36(25):3923-3934
pubmed: 28748567
JAMA. 2019 Aug 13;322(6):524-534
pubmed: 31408137
Am J Hypertens. 1997 Aug;10(8):829-35
pubmed: 9270076
Res Synth Methods. 2016 Mar;7(1):55-79
pubmed: 26332144
Stroke. 1993 Sep;24(9):1347-51
pubmed: 8362429
Am J Cardiol. 1999 Feb 1;83(3):367-70
pubmed: 10072225
Am J Hypertens. 2001 Dec;14(12):1226-30
pubmed: 11775131
J Electrocardiol. 2010 May-Jun;43(3):209-14
pubmed: 20004413
Stroke. 2014 Dec;45(12):3567-75
pubmed: 25388424
JAMA Psychiatry. 2017 Jul 1;74(7):729-739
pubmed: 28564681
Hypertension. 2015 Dec;66(6):1152-8
pubmed: 26503971
JAMA Neurol. 2019 Jan 1;76(1):81-94
pubmed: 30422209
BMC Med Res Methodol. 2015 Nov 14;15:99
pubmed: 26573817
J Hypertens. 2012 May;30(5):990-6
pubmed: 22441347
N Engl J Med. 1990 May 31;322(22):1561-6
pubmed: 2139921
Neurology. 2019 Mar 19;92(12):e1298-e1308
pubmed: 30770431
Hypertens Res. 2011 Apr;34(4):530-5
pubmed: 21228785
Ann Intern Med. 2014 Feb 18;160(4):267-70
pubmed: 24727843
J Am Med Dir Assoc. 2017 May 1;18(5):451.e13-451.e25
pubmed: 28279605
Stroke. 2003 Oct;34(10):2380-4
pubmed: 12958319
J Epidemiol Community Health. 2002 Feb;56 Suppl 1:i8-13
pubmed: 11815638
J Stroke Cerebrovasc Dis. 2015 Sep;24(9):1991-7
pubmed: 26153509
Biometrics. 2000 Jun;56(2):455-63
pubmed: 10877304
Am Heart J. 2017 Mar;185:85-92
pubmed: 28267479
Stroke. 1991 Mar;22(3):312-8
pubmed: 2003301
J Res Natl Inst Stand Technol. 1989 May-Jun;94(3):197-203
pubmed: 28053410
Ann Med. 2017 Nov;49(7):562-568
pubmed: 28657357
Am J Hypertens. 2002 Jun;15(6):507-12
pubmed: 12074351
JAMA. 1994 Jul 6;272(1):33-6
pubmed: 8007076
J Am Heart Assoc. 2017 Dec 15;6(12):
pubmed: 29246962
Hypertension. 2017 Nov;70(5):964-971
pubmed: 28893898
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
Stroke. 2008 Nov;39(11):2929-35
pubmed: 18583555
Lancet Neurol. 2010 Jul;9(7):689-701
pubmed: 20610345
Stroke. 1997 Mar;28(3):491-9
pubmed: 9056601
Stroke. 2003 Jul;34(7):1766-70
pubmed: 12805496
J Am Coll Cardiol. 1998 Jun;31(7):1635-40
pubmed: 9626845
Neurology. 2004 Jul 13;63(1):16-21
pubmed: 15249604
BMC Med Res Methodol. 2014 Feb 18;14:25
pubmed: 24548571
Stroke. 2006 Oct;37(10):2493-8
pubmed: 16931783
JAMA. 2000 Apr 19;283(15):2008-12
pubmed: 10789670
Am Heart J. 2001 May;141(5):784-91
pubmed: 11320367
Am J Kidney Dis. 2006 Feb;47(2):241-50
pubmed: 16431253
Neurology. 2012 Jan 10;78(2):102-8
pubmed: 22170882
JAMA Neurol. 2018 Jan 1;75(1):80-87
pubmed: 29114731
Stat Med. 2008 Mar 30;27(7):954-70
pubmed: 17676579
Stat Med. 2001 Jun 30;20(12):1771-82
pubmed: 11406840
Stroke. 2010 Aug;41(8):1652-8
pubmed: 20576951
Geriatr Gerontol Int. 2014 Apr;14 Suppl 2:71-6
pubmed: 24650068
J Hypertens. 2009 Apr;27(4):846-53
pubmed: 19300113
J Am Heart Assoc. 2018 Dec 18;7(24):e008992
pubmed: 30526268
Res Synth Methods. 2019 Dec;10(4):515-527
pubmed: 31111673
J Stroke Cerebrovasc Dis. 2019 Jul;28(7):1897-1901
pubmed: 31029567
J Stroke Cerebrovasc Dis. 2018 Jul;27(7):1815-1821
pubmed: 29576397
Eur Heart J. 2018 Sep 1;39(33):3021-3104
pubmed: 30165516
Clin Exp Pharmacol Physiol. 1991 Sep;18(9):605-10
pubmed: 1835681
N Engl J Med. 2001 May 10;344(19):1450-60
pubmed: 11346811
Hypertens Res. 2017 Jul;40(7):696-709
pubmed: 28202945
Stat Med. 2019 Sep 10;38(20):3804-3816
pubmed: 31209917
Hypertension. 2018 Mar;71(3):429-436
pubmed: 29378853
J Stroke. 2015 May;17(2):111-22
pubmed: 26060798
Eur Heart J Cardiovasc Imaging. 2015 Jun;16(6):577-605
pubmed: 25995329
J Am Heart Assoc. 2018 Jun 26;7(13):
pubmed: 29945917
JAMA. 2004 Nov 17;292(19):2343-9
pubmed: 15547161
BMJ. 2009 Jul 06;339:b2477
pubmed: 19581317
J Neurol. 2007 Mar;254(3):284-9
pubmed: 17345053
Eur J Heart Fail. 2007 Oct;9(10):1003-9
pubmed: 17719270
Lancet Neurol. 2019 Jul;18(7):684-696
pubmed: 31097385
Acta Neurol Scand. 1996 Aug;94(2):137-44
pubmed: 8891060
Blood Press. 2016 Jun;25(3):149-54
pubmed: 26581453
Hypertension. 1994 Jan;23(1 Suppl):I259-62
pubmed: 8282371
Am J Hypertens. 2010 Aug;23(8):876-81
pubmed: 20414193
Stroke. 2000 Nov;31(11):2616-22
pubmed: 11062284
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120